Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Translational Neurodegeneration
Published in: Translational Neurodegeneration 1/2019

Open Access 01-12-2019 | Alzheimer's Disease | Research

Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer’s disease and associated with CSF-TAU and FDG-PET

Authors: Oliver Goldhardt, Inanna Warnhoff, Igor Yakushev, Ilijana Begcevic, Hans Förstl, Viktor Magdolen, Antoninus Soosaipillai, Eleftherios Diamandis, Panagiotis Alexopoulos, Timo Grimmer

Published in: Translational Neurodegeneration | Issue 1/2019

Login to get access

Abstract

Background

Alterations in the expression of human kallikrein-related peptidases (KLKs) have been described in patients with Alzheimer’s disease (AD). We elucidated the suitability of KLK6, KLK8 and KLK10 to distinguish AD from NC and explored associations with established AD biomarkers.

Methods

KLK levels in cerebrospinal fluid (CSF), as determined by ELISA, were compared between 32 AD patients stratified to A/T/(N) system with evidence for amyloid pathology and of 23 normal controls with normal AD biomarkers. Associations between KLK levels and clinical severity, CSF and positron emission tomography (PET) based AD biomarkers were tested for.

Results

Levels of KLK6 and KLK10 were significantly increased in AD. KLK6 differed significantly between AD A+/T+/N+ and AD A+/T−/N+ or NC with an AUC of 0.922. CSF pTau and tTau levels were significantly associated with KLK6 in AD.

Conclusions

KLK6 deserves further investigations as a potential biomarker of Tau pathology in AD.
Appendix
Available only for authorised users
Literature
1.
Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol. 2015;11(8):457–70.PubMedPubMedCentralCrossRef
2.
Thal DR, Rüb U, Orantes M, Braak H. Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791–800.PubMedCrossRef
3.
Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med Off Publ Soc Nucl Med. 2000;41(11):1920–8.
4.
Tapiola T, Alafuzoff I, Herukka S-K, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382–9.PubMedCrossRef
5.
Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BNM, et al. Prevalence of amyloid PET positivity in dementia syndromes. JAMA. 2015;313(19):1939–49.PubMedPubMedCentralCrossRef
6.
Prassas I, Eissa A, Poda G, Diamandis EP. Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nat Rev Drug Discov. 2015;14(3):183–202.PubMedCrossRef
7.
Pericak-Vance MA, Bebout JL, Gaskell PC, Yamaoka LH, Hung W-Y, Alberts MJ, et al. Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. Am J Hum Genet. 1991;48(6):1034–50.PubMedPubMedCentral
8.
Shaw JLV, Diamandis EP. Distribution of 15 human Kallikreins in tissues and biological fluids. Clin Chem. 2007;53(8):1423–32.PubMedCrossRef
9.
Shimizu-Okabe C, Yousef GM, Diamandis EP, Yoshida S, Shiosaka S, Fahnestock M. Expression of the kallikrein gene family in normal and Alzheimer’s disease brain. Neuroreport. 2001;12(12):2747–51.PubMedCrossRef
10.
Kalinska M, Meyer-Hoffert U, Kantyka T, Potempa J. Kallikreins - the melting pot of activity and function. Biochimie. 2016;122:270–82.PubMedCrossRef
11.
Diamandis EP, Yousef GM, Soosaipillai AR, Grass L, Porter A, Little S, et al. Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem. 2000;33(5):369–75.PubMedCrossRef
12.
Diamandis EP, Yousef GM, Petraki C, Soosaipillai AR. Human Kallikrein 6 as a biomarker of Alzheimer’s disease. Clin Biochem. 2000;33(8):663–7.PubMedCrossRef
13.
Mitsui S, Okui A, Uemura H, Mizuno T, Yamada T, Yamamura Y, et al. Decreased cerebrospinal fluid levels of Neurosin (KLK6), an aging-related protease, as a possible new risk factor for Alzheimer’s disease. Ann N Y Acad Sci. 2002;977(1):216–23.PubMedCrossRef
14.
Petraki CD, Karavana VN, Skoufogiannis PT, Little SP, Howarth DJ, Yousef GM, et al. The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem Off J Histochem Soc. 2001;49(11):1431–41.CrossRef
15.
Ashby EL, Kehoe PG, Love S. Kallikrein-related peptidase 6 in Alzheimer’s disease and vascular dementia. Brain Res. 2010;1363:1–10.PubMedCrossRef
16.
17.
Scarisbrick IA, Isackson PJ, Ciric B, Windebank AJ, Rodriguez M. MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system. J Comp Neurol. 2001;431(3):347–61.PubMedCrossRef
18.
Scarisbrick IA, Radulovic M, Burda JE, Larson N, Blaber SI, Giannini C, et al. Kallikrein 6 is a novel molecular trigger of reactive astrogliosis. Biol Chem. 2012;393(5):355–67.PubMedPubMedCentralCrossRef
19.
Iwata A, Maruyama M, Akagi T, Hashikawa T, Kanazawa I, Tsuji S, et al. Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum Mol Genet. 2003;12(20):2625–35.PubMedCrossRef
20.
Little SP, Dixon EP, Norris F, Buckley W, Becker GW, Johnson M, et al. Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer’s disease brain. J Biol Chem. 1997;272(40):25135–42.PubMedCrossRef
21.
Shimizu C, Yoshida S, Shibata M, Kato K, Momota Y, Matsumoto K, et al. Characterization of recombinant and brain Neuropsin, a plasticity-related serine protease. J Biol Chem. 1998;273(18):11189–96.PubMedCrossRef
22.
Zarghooni M, Soosaipillai A, Grass L, Scorilas A, Mirazimi N, Diamandis EP. Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer’s disease patients. Clin Biochem. 2002;35(3):225–31.PubMedCrossRef
23.
Dukic L, Simundic A-M, Martinic-Popovic I, Kackov S, Diamandis A, Begcevic I, et al. The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia. Clin Biochem. 2016;49(3):213–8.PubMedCrossRef
24.
Patra K, Soosaipillai A, Sando SB, Lauridsen C, Berge G, Møller I, et al. Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease. Alzheimers Res Ther. 2018;10(1):9.
25.
Attwood B, Bourgognon J-M, Patel S, Mucha M, Schiavon E, Skrzypiec AE, et al. Neuropsin cleaves EphB2 in the amygdala to control anxiety. Nature. 2011;473(7347):372–5.PubMedPubMedCentralCrossRef
26.
Cissé M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature. 2011;469(7328):47–52.PubMedCrossRef
27.
28.
Qu M, Jiang J, Liu X-P, Tian Q, Chen L-M, Yin G, et al. Reduction and the intracellular translocation of EphB2 in Tg2576 mice and the effects of β-amyloid. Neuropathol Appl Neurobiol. 2013;39(6):612–22.PubMedCrossRef
29.
Simón AM, de Maturana RL, Ricobaraza A, Escribano L, Schiapparelli L, Cuadrado-Tejedor M, et al. Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer’s disease. J Alzheimers Dis JAD. 2009;17(4):773–86.PubMedCrossRef
30.
Herring A, Münster Y, Akkaya T, Moghaddam S, Deinsberger K, Meyer J, et al. Kallikrein-8 inhibition attenuates Alzheimer’s disease pathology in mice. Alzheimers Dement J Alzheimers Assoc. 2016;12(12):1273–87.CrossRef
31.
Keyvani K, Münster Y, Kurapati NK, Rubach S, Schönborn A, Kocakavuk E, et al. Higher levels of kallikrein-8 in female brain may increase the risk for Alzheimer’s disease. Brain Pathol Zurich Switz. 2018;28(6):947–64.CrossRef
32.
Petraki CD, Karavana VN, Luo L-Y, Diamandis EP. Human kallikrein 10 expression in normal tissues by immunohistochemistry. J Histochem Cytochem Off J Histochem Soc. 2002;50(9):1247–61.CrossRef
33.
Diamandis EP, Scorilas A, Kishi T, Blennow K, Luo L-Y, Soosaipillai A, et al. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer’s disease and frontotemporal dementia. Clin Biochem. 2004;37(3):230–7.PubMedCrossRef
34.
35.
Schain M, Kreisl WC. Neuroinflammation in neurodegenerative disorders-a review. Curr Neurol Neurosci Rep. 2017;17(3):25.PubMedCrossRef
36.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.PubMedCrossRef
37.
Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part I. clinical and neuropsychological assessment of Alzheimer’s disease. Neurology. 1989;39(9):1159–65.CrossRefPubMed
38.
Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4.PubMedCrossRef
39.
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc. 2011;7(3):270–9.CrossRef
40.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc. 2011;7(3):263–9.CrossRef
41.
Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology. 1999;52(8):1555–62.PubMedCrossRef
42.
Berres M, Monsch AU, Bernasconi F, Thalmann B, Stähelin HB. Normal ranges of neuropsychological tests for the diagnosis of Alzheimer’s disease. Stud Health Technol Inform. 2000;77:195–9.PubMed
43.
Zivelin A, Rosenberg N, Peretz H, Amit Y, Kornbrot N, Seligsohn U. Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. Clin Chem. 1997;43(9):1657–9.PubMed
44.
Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med Off Publ Soc Nucl Med. 1995;36(7):1238–48.
45.
Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69(9):871–7.PubMedCrossRef
46.
Grimmer T, Henriksen G, Wester HJ, Forstl H, Klunk WE, Mathis CA, et al. Clinical severity of Alzheimer’s disease is associated with PIB uptake in PET. Neurobiol Aging. 2009;30(12):1902–9.PubMedCrossRef
47.
Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, Mathis CA, et al. Beta amyloid in Alzheimer’s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry. 2009;65(11):927–34.PubMedPubMedCentralCrossRef
48.
Grimmer T, Tholen S, Yousefi BH, Alexopoulos P, Forschler A, Forstl H, et al. Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer’s disease. Biol Psychiatry. 2010;68(10):879–84.PubMedPubMedCentralCrossRef
49.
Goos JDC, Henneman WJP, Sluimer JD, Vrenken H, Sluimer IC, Barkhof F, et al. Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurology. 2010;74(24):1954–60.PubMedCrossRef
50.
Tsolakidou A, Alexopoulos P, Guo L-H, Grimmer T, Westerteicher C, Kratzer M, et al. β-Site amyloid precursor protein-cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau. Alzheimers Dement J Alzheimers Assoc. 2013;9(4):386–91.CrossRef
51.
Luo L-Y, Grass L, Howarth DJC, Thibault P, Ong H, Diamandis EP. Immunofluorometric assay of human Kallikrein 10 and its identification in biological fluids and tissues. Clin Chem. 2001;47(2):237–46.PubMed
52.
Kishi T, Grass L, Soosaipillai A, Shimizu-Okabe C, Diamandis EP. Human Kallikrein 8: immunoassay development and identification in tissue extracts and biological fluids. Clin Chem. 2003;49(1):87–96.PubMedCrossRef
53.
Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539–47.PubMedPubMedCentralCrossRef
54.
Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc. 2018;14(4):535–62.CrossRef
55.
Khachaturian ZS, Radebaugh TS. Consensus report of the working group on: “molecular and biochemical markers of Alzheimer’s disease” 11The names of the working group members and the names of the working group advisory committee members are listed in the appendix a(section VI). 22The Reagan institute working groups are planned and organized by Z. S. Khachaturian and T.S. Radebaugh; fax: 301-879-2023; E-mail: zaven@idt.net. Neurobiol Aging. 1998;19(2):109–16.CrossRef
56.
57.
Buerger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain J Neurol. 2006;129(Pt 11):3035–41.CrossRef
58.
Thal DR. The pre-capillary segment of the blood-brain barrier and its relation to perivascular drainage in Alzheimer’s disease and small vessel disease. ScientificWorldJournal. 2009;9:557–63.PubMedPubMedCentralCrossRef
59.
Akiyama H, Kondo H, Ikeda K, Kato M, McGeer PL. Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid beta-protein (Abeta) deposition. Brain Res. 2001;902(2):277–81.PubMedCrossRef
60.
Yasojima K, McGeer EG, McGeer PL. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res. 2001;919(1):115–21.PubMedCrossRef
61.
Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, et al. Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun. 2003;307(4):948–55.PubMedCrossRef
62.
63.
Rajapakse S, Ogiwara K, Takano N, Moriyama A, Takahashi T. Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins. FEBS Lett. 2005;579(30):6879–84.PubMedCrossRef
64.
Debela M, Magdolen V, Bode W, Brandstetter H, Goettig P. Structural basis for the Zn2+ inhibition of the zymogen-like kallikrein-related peptidase 10. Biol Chem. 2016;397(12):1251–64.PubMedPubMedCentralCrossRef
65.
Grimmer T, Faust M, Auer F, Alexopoulos P, Förstl H, Henriksen G, et al. White matter hyperintensities predict amyloid increase in Alzheimer’s disease. Neurobiol Aging. 2012;33(12):2766–73.PubMedCrossRef
66.
Bando Y, Hagiwara Y, Suzuki Y, Yoshida K, Aburakawa Y, Kimura T, et al. Kallikrein 6 secreted by oligodendrocytes regulates the progression of experimental autoimmune encephalomyelitis. Glia. 2018;66(2):359–78.PubMedCrossRef
67.
Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Blaber M, Blaber SI, et al. Proteinase-activated receptors, targets for Kallikrein signaling. J Biol Chem. 2006;281(43):32095–112.PubMedCrossRef
68.
Angelo PF, Lima AR, Alves FM, Blaber SI, Scarisbrick IA, Blaber M, et al. Substrate specificity of human Kallikrein 6 salt and glycosaminoglycan activation effects. J Biol Chem. 2006;281(6):3116–26.PubMedCrossRef
69.
Hebb ALO, Bhan V, Wishart AD, Moore CS, Robertson GS. Human kallikrein 6 cerebrospinal levels are elevated in multiple sclerosis. Curr Drug Discov Technol. 2010;7(2):137–40.PubMedCrossRef
Metadata
Title
Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer’s disease and associated with CSF-TAU and FDG-PET
Authors
Oliver Goldhardt
Inanna Warnhoff
Igor Yakushev
Ilijana Begcevic
Hans Förstl
Viktor Magdolen
Antoninus Soosaipillai
Eleftherios Diamandis
Panagiotis Alexopoulos
Timo Grimmer
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Translational Neurodegeneration / Issue 1/2019
Electronic ISSN: 2047-9158
DOI
https://doi.org/10.1186/s40035-019-0168-6

Other articles of this Issue 1/2019

Translational Neurodegeneration 1/2019 Go to the issue

Review

Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities

Research

Suppression of astrocytic autophagy by αB-crystallin contributes to α-synuclein inclusion formation

Review

Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in

Research

Transplantation of bone marrow derived macrophages reduces markers of neuropathology in an APP/PS1 mouse model

Research

A longitudinal assessment of retinal function and structure in the APP/PS1 transgenic mouse model of Alzheimer’s disease

Review

Parkinson’s disease in China: a forty-year growing track of bedside work